Makers of smartwatches and other wearables have spent years trying to measure blood sugar without pricking your skin. The ...

The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteersPhase 2 trial will assess ...

Apple Watch blood sugar monitoring is something the company reportedly wanted to do right from the start. A report ...

Luma Vision announced that it completed 15 AFib ablation procedures as part of a clinical study in collaboration with CardioFocus.

AliveCor’s latest attempt to revive its Apple Watch antitrust case fell short this week, with a federal appeals court ...

In addition to its climate results, Arkema also maintained its “A-” rating in the CDP Water Security category. Together, these scores highlight the group’s continued commitment to addressing climate ...

Allianz SE and Anthropic have announced a global partnership focused on deploying responsible, safety-first artificial intelligence across Allianz’s insurance operations. The collaboration targets ...